You are viewing a preview of this course. Sign in to start learning

Lesson 5: Antimicrobial Pharmacology - Antibiotics and Resistance

Explores major antibiotic classes, their mechanisms of action, spectrum of activity, side effects, and the growing threat of antimicrobial resistance

Lesson 5: Antimicrobial Pharmacology - Antibiotics and Resistance πŸ¦ πŸ’Š

Introduction

Welcome to one of the most clinically crucial areas of pharmacology! After mastering autonomic, cardiovascular, and CNS drugs in previous lessons, we now turn our attention to antimicrobial agents - drugs that fight infections caused by bacteria, fungi, viruses, and parasites. This lesson focuses specifically on antibiotics (antibacterial agents), which have revolutionized medicine since penicillin's discovery in 1928.

🌍 Real-world context: Imagine a patient presenting to the emergency department with pneumonia. The physician must rapidly decide: Which antibiotic? What spectrum of coverage? What route of administration? Understanding antibiotic pharmacology literally means the difference between life and death.

However, our antibiotic arsenal faces an unprecedented threat: antimicrobial resistance (AMR). The World Health Organization calls AMR one of the top 10 global public health threats. By 2050, drug-resistant infections could cause 10 million deaths annually if current trends continue.

In this lesson, you'll learn:

  • 🧬 How different antibiotic classes kill or inhibit bacteria
  • 🎯 Spectrum of activity (which bugs each drug covers)
  • ⚠️ Major side effects and contraindications
  • πŸ›‘οΈ Mechanisms of antimicrobial resistance
  • πŸ’‘ Clinical decision-making principles

Let's dive into the fascinating world where chemistry meets microbiology meets clinical medicine!


Core Concepts: Understanding Antibiotic Pharmacology

πŸ”¬ Fundamental Principles: Bactericidal vs. Bacteriostatic

Antibiotics work through two fundamental approaches:

Bactericidal agents = "Bacteria killers" πŸ’€

  • Directly kill bacteria
  • Essential for immunocompromised patients, endocarditis, meningitis
  • Examples: Beta-lactams, fluoroquinolones, aminoglycosides

Bacteriostatic agents = "Bacteria stoppers" ⏸️

  • Inhibit bacterial growth/reproduction
  • Rely on host immune system to clear infection
  • Examples: Tetracyclines, macrolides, sulfonamides

πŸ’‘ Clinical tip: This distinction matters! In a patient with severe neutropenia (very low white blood cells), bacteriostatic drugs may fail because the immune system can't finish the job.

🎯 Spectrum of Activity

πŸ“Š Antibiotic Spectrum Categories

Spectrum TypeCoverageExample Drugs
Narrow-spectrumFew bacterial species (Gram+ OR Gram-)Penicillin G (Gram+), Vancomycin (Gram+)
Broad-spectrumMany species (both Gram+ AND Gram-)Amoxicillin-clavulanate, Ceftriaxone
Extended-spectrumBroad coverage + specific resistant organismsPiperacillin-tazobactam, Meropenem

🧠 Memory aid - "SPECTRUM":

  • Select narrow when organism known
  • Prevent resistance with appropriate choice
  • Extended for severe/hospital infections
  • Cultures guide de-escalation
  • Target therapy beats shotgun approach
  • Resistance rises with broad-spectrum overuse
  • Use empiric broad coverage for sepsis
  • Microbiome preservation matters

🧬 Bacterial Structure: Know Your Target

To understand how antibiotics work, we must understand bacterial anatomy:

β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
β”‚        BACTERIAL CELL STRUCTURE             β”‚
β”œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€
β”‚                                             β”‚
β”‚     🧱 Cell Wall (peptidoglycan)           β”‚
β”‚        ↑                                    β”‚
β”‚        β”‚ Target: Beta-lactams               β”‚
β”‚                                             β”‚
β”‚     🧬 DNA/RNA Synthesis                   β”‚
β”‚        ↑                                    β”‚
β”‚        β”‚ Target: Fluoroquinolones           β”‚
β”‚                                             β”‚
β”‚     🏭 Ribosomes (30S/50S)                 β”‚
β”‚        ↑                                    β”‚
β”‚        β”‚ Target: Aminoglycosides,           β”‚
β”‚        β”‚         Macrolides, Tetracyclines  β”‚
β”‚                                             β”‚
β”‚     πŸ”§ Folic Acid Synthesis                β”‚
β”‚        ↑                                    β”‚
β”‚        β”‚ Target: Sulfonamides, Trimethoprim β”‚
β”‚                                             β”‚
β””β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”˜

Major Antibiotic Classes: Mechanisms and Clinical Use

1️⃣ Beta-Lactam Antibiotics 🧱

The most widely used antibiotic class in the world!

Mechanism of Action: Inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing peptidoglycan cross-linking. Without a sturdy cell wall, bacteria undergo osmotic lysis and die. ⚰️

Subclasses:

SubclassExamplesSpectrumClinical Use
PenicillinsPenicillin G, Amoxicillin, PiperacillinNarrow to broad (depending on agent)Strep throat, syphilis, community infections
CephalosporinsCeftriaxone (3rd gen), Cefepime (4th gen)Broad, increasing Gram- with higher generationsPneumonia, meningitis, sepsis
CarbapenemsMeropenem, ImipenemExtended (last-resort agents)Multi-drug resistant infections
MonobactamsAztreonamGram- onlyPenicillin-allergic patients

Key Side Effects:

  • πŸ”΄ Hypersensitivity reactions: Ranging from rash (5-10% of patients) to life-threatening anaphylaxis (0.05%)
  • 🧠 Remember: 10% cross-reactivity between penicillins and cephalosporins (but aztreonam is safe!)
  • πŸ’© GI disturbances: Nausea, diarrhea, Clostridioides difficile colitis
  • 🩸 Hematologic effects: Platelet dysfunction with high-dose piperacillin

Resistance Mechanisms:

  1. Beta-lactamase enzymes: Bacteria produce enzymes that cleave the beta-lactam ring
    • Solution: Add beta-lactamase inhibitors (clavulanate, tazobactam, sulbactam)
  2. Altered PBPs: Target site modification (MRSA has altered PBP2a)
  3. Reduced permeability: Porin channel mutations prevent drug entry

2️⃣ Aminoglycosides 🏭

Examples: Gentamicin, Tobramycin, Amikacin

Mechanism of Action: Bind irreversibly to the 30S ribosomal subunit, causing:

  1. Misreading of mRNA (wrong amino acids incorporated)
  2. Premature termination of protein synthesis
  3. Bactericidal effect through production of toxic proteins

Spectrum: Gram-negative bacteria (excellent), some aerobic Gram-positive

Clinical Pearls πŸ’Ž:

  • Concentration-dependent killing: High peak levels kill more effectively
  • Post-antibiotic effect: Bacteria remain suppressed even after drug cleared
  • Synergy with beta-lactams: Combined for endocarditis, severe sepsis
  • Once-daily dosing: Maximizes efficacy, may reduce toxicity

Major Side Effects ⚠️:

  1. Nephrotoxicity (kidney damage): 5-25% of patients

    • Accumulates in renal cortex
    • Monitor: Serum creatinine, trough levels
    • Reversible with early detection
  2. Ototoxicity (hearing/balance loss): 2-10% of patients

    • Damages cochlear and vestibular hair cells
    • IRREVERSIBLE - major concern!
    • Monitor: Audiometry, patient symptoms (tinnitus, vertigo)
  3. Neuromuscular blockade: Rare but serious

    • Enhanced by anesthetics, calcium channel blockers
    • Can cause respiratory paralysis

πŸ’‘ Dosing tip: "Trough before peak" - check trough level (before next dose) first to ensure adequate clearance, then adjust dose based on peak level for efficacy.

3️⃣ Fluoroquinolones 🧬

Examples: Ciprofloxacin, Levofloxacin, Moxifloxacin

Mechanism of Action: Inhibit bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication and repair. Without these enzymes, DNA breaks accumulate β†’ bacterial death.

Spectrum: Broad-spectrum with excellent Gram-negative coverage; respiratory fluoroquinolones (levofloxacin, moxifloxacin) cover atypical pneumonia pathogens

Clinical Uses:

  • UTIs (ciprofloxacin is first-line)
  • Respiratory infections
  • Bone/joint infections (excellent bone penetration)
  • GI infections (Salmonella, Campylobacter)
  • Anthrax exposure (post-exposure prophylaxis)

Notable Side Effects 🚨:

⚠️ FDA Black Box Warnings for Fluoroquinolones

  • Tendon rupture: Achilles tendon most common, risk increases with age >60, corticosteroids, transplants
  • Peripheral neuropathy: Potentially permanent nerve damage
  • CNS effects: Seizures, psychiatric disturbances, confusion (especially elderly)
  • Aortic aneurysm/dissection: Avoid in patients with risk factors
  • QT prolongation: Risk of fatal arrhythmias (torsades de pointes)

Drug Interactions:

  • πŸ₯› Chelation: Divalent/trivalent cations (Ca²⁺, Mg²⁺, Fe³⁺, Al³⁺) reduce absorption
    • Clinical impact: Don't take with dairy, antacids, or multivitamins
    • Space doses 2-6 hours apart
  • πŸ’Š Theophylline: Fluoroquinolones increase levels (toxicity risk)
  • πŸ’— QT-prolonging drugs: Additive effect (amiodarone, antipsychotics)

🧠 Memory trick - "FLUOROQUINOLONES = FRAGILE":

  • FDA warnings (multiple black boxes)
  • Rupture (tendons)
  • Aortic problems
  • GI upset common
  • Interactions (chelation)
  • Long QT
  • Excellent oral bioavailability

4️⃣ Macrolides 🏭

Examples: Erythromycin, Azithromycin (Z-pack), Clarithromycin

Mechanism of Action: Bind to the 50S ribosomal subunit, blocking translocation of peptidyl-tRNA from A site to P site. This inhibits protein elongation β†’ bacteriostatic effect.

Spectrum: Gram-positive cocci, atypical pneumonia (Mycoplasma, Chlamydia, Legionella)

Clinical Use:

  • Community-acquired pneumonia (often combined with beta-lactam)
  • Atypical infections: Whooping cough, Chlamydia STI
  • Penicillin alternative: For strep throat in allergic patients
  • Non-antibiotic uses: Azithromycin for chronic lung disease (anti-inflammatory effects)

Side Effects:

  • πŸ’© GI effects: Nausea, diarrhea (erythromycin is motilin agonist β†’ cramps)
  • πŸ’— QT prolongation: Especially azithromycin (FDA warning 2013)
  • πŸ„ Hepatotoxicity: Cholestatic jaundice with erythromycin
  • πŸ”΄ Eosinophilic pneumonia: Rare hypersensitivity reaction

Drug Interactions (Important! 🚨):

  • CYP3A4 inhibition: Macrolides (except azithromycin) inhibit this enzyme
    • Increases levels of: Statins (rhabdomyolysis risk), warfarin, cyclosporine
    • Clinical tip: Azithromycin doesn't inhibit CYP enzymes - safer choice with multiple meds

5️⃣ Tetracyclines 🏭

Examples: Doxycycline, Tetracycline, Tigecycline

Mechanism of Action: Bind to 30S ribosomal subunit (different site than aminoglycosides), preventing aminoacyl-tRNA from binding to A site. This blocks protein synthesis β†’ bacteriostatic.

Spectrum: Broad-spectrum including atypicals, intracellular organisms (Rickettsia, Chlamydia), Borrelia (Lyme disease)

Clinical Applications:

  • Doxycycline = "travel medicine drug": Malaria prophylaxis, rickettsial infections, Lyme disease, acne
  • MRSA skin infections (doxycycline, minocycline)
  • Severe acne (anti-inflammatory + antibacterial)

Side Effects & Contraindications:

EffectMechanismClinical Significance
Teeth staining 🦷Chelates calcium in developing teethCONTRAINDICATED in children <8 years, pregnancy
Bone growth inhibitionBinds calcium in growing bonesAvoid in pregnancy, children
Photosensitivity β˜€οΈPhototoxic reactionWarn patients: Use sunscreen!
GI upsetDirect irritationTake with food (except dairy)
EsophagitisPill lodging in esophagusTake with water, remain upright 30 min

⚠️ Pregnancy category D: Can cause permanent effects on developing fetus!

6️⃣ Glycopeptides 🧱

Examples: Vancomycin, Teicoplanin

Mechanism of Action: Large molecules that bind to D-Ala-D-Ala terminus of peptidoglycan precursors, preventing incorporation into cell wall. Too large to penetrate Gram-negative outer membrane.

Spectrum: Gram-positive ONLY (including MRSA, C. difficile)

Clinical Uses:

  • MRSA infections: Serious infections when beta-lactams fail
  • Severe C. difficile colitis: Oral vancomycin (not absorbed systemically)
  • Endocarditis prophylaxis: In penicillin-allergic patients
  • Empiric sepsis coverage: Until cultures identify organism

Major Side Effects:

  1. "Red Man Syndrome" πŸ”΄: Not an allergy!

    • Histamine release from rapid infusion
    • Symptoms: Flushing, pruritus, hypotension
    • Prevention: Slow infusion (>60 minutes), antihistamine premedication
  2. Nephrotoxicity πŸ’§: 5-15% of patients

    • Risk increases with: Aminoglycosides, loop diuretics, prolonged therapy
    • Monitor: Serum creatinine, vancomycin trough levels
  3. Ototoxicity πŸ‘‚: Less common than aminoglycosides but can occur

πŸ’‘ Therapeutic drug monitoring: Target trough levels 15-20 mcg/mL for serious infections, 10-15 mcg/mL for less serious infections.


πŸ›‘οΈ Antimicrobial Resistance: The Growing Crisis

β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
β”‚   HOW RESISTANCE DEVELOPS & SPREADS         β”‚
β””β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”˜

  🦠 Bacterial Population
      β”‚
      ↓
  πŸ’Š Antibiotic Exposure
      β”‚
  β”Œβ”€β”€β”€β”΄β”€β”€β”€β”
  β”‚       β”‚
  ↓       ↓
Die    Resistant mutant survives
        β”‚
        ↓
    🧬 Reproduction
        β”‚
        ↓
    🦠🦠🦠 Resistant colony dominates
        β”‚
    β”Œβ”€β”€β”€β”΄β”€β”€β”€β”¬β”€β”€β”€β”€β”€β”€β”€β”
    ↓       ↓       ↓
  πŸ”„DNA   πŸ’‰Patient   🌍 Environment
 Transfer  Spread    Contamination

Mechanisms of Resistance

1. Enzymatic Inactivation πŸ”§

  • Beta-lactamases: Break beta-lactam ring
    • ESBLs (Extended-Spectrum Beta-Lactamases): Resist most cephalosporins
    • Carbapenemases (KPC, NDM): Resist carbapenems ("superbugs")
  • Aminoglycoside-modifying enzymes: Add chemical groups

2. Target Modification 🎯

  • MRSA: Altered PBP2a has low affinity for all beta-lactams
  • VRE (Vancomycin-Resistant Enterococci): Changes D-Ala-D-Ala to D-Ala-D-Lac
  • Ribosomal methylation: Prevents macrolide/aminoglycoside binding

3. Reduced Permeability πŸšͺ

  • Porin mutations: Decrease drug entry (Gram-negatives)
  • Outer membrane changes: Thicker, altered lipopolysaccharide

4. Efflux Pumps ⬆️

  • Active transport systems pump drug out
  • Can be non-specific (multiple drug classes)
  • Major mechanism for fluoroquinolone, tetracycline resistance

🌍 Notable Resistant Organisms (Know These!)

🦠 "ESKAPE" Pathogens - Leading Cause of Hospital Infections

  • Enterococcus faecium (VRE)
  • Staphylococcus aureus (MRSA)
  • Klebsiella pneumoniae (Carbapenem-resistant)
  • Acinetobacter baumannii (Multi-drug resistant)
  • Pseudomonas aeruginosa (Multi-drug resistant)
  • Enterobacter species (Carbapenem-resistant)

πŸ’Š Combating Resistance: Clinical Strategies

Antimicrobial Stewardship Programs aim to:

  1. βœ… Use antibiotics only when needed: No antibiotics for viral infections!
  2. 🎯 Choose the narrowest spectrum: "Big guns" reserved for resistant infections
  3. ⏱️ Optimize dosing: Adequate dose and duration
  4. πŸ”¬ Use cultures to guide therapy: De-escalate based on sensitivity testing
  5. πŸ“š Educate prescribers and patients: Understanding drives appropriate use

πŸ€” Did you know? 30% of antibiotics prescribed in outpatient settings are unnecessary. Upper respiratory infections (colds, flu) are viral 90% of the time, yet often receive antibiotics.


Clinical Examples: Applying Antibiotic Knowledge πŸ₯

Example 1: Community-Acquired Pneumonia (CAP)

Clinical Scenario: A 45-year-old man presents with fever (39Β°C), productive cough with rusty sputum, and right-sided chest pain. Chest X-ray shows right lower lobe consolidation. No significant medical history. Vitals stable.

Clinical Reasoning Process:

QuestionAnswerClinical Implication
Where acquired?Community (not hospital)Lower resistance rates expected
Likely pathogens?Streptococcus pneumoniae (most common), Haemophilus influenzae, atypicalsNeed Gram+ AND atypical coverage
Severity?Moderate (stable vitals)Oral therapy acceptable
Risk factors?None notedStandard empiric therapy

Antibiotic Selection:

  • First choice: Amoxicillin-clavulanate + Azithromycin
    • Rationale: Beta-lactam covers typical bacteria, macrolide covers atypicals
  • Alternative (if penicillin allergy): Respiratory fluoroquinolone (levofloxacin or moxifloxacin) monotherapy
    • Rationale: Covers both typical and atypical pathogens

Why not other options?

  • ❌ Vancomycin: Overkill, MRSA unlikely in community CAP without risk factors
  • ❌ Ciprofloxacin alone: Poor S. pneumoniae coverage
  • ❌ Aminoglycosides: Atypicals are intracellular (aminoglycosides don't penetrate cells well)

Example 2: Healthcare-Associated UTI with Resistance

Clinical Scenario: A 72-year-old woman develops fever and dysuria on day 4 of hospitalization after hip surgery. Urine culture grows E. coli resistant to ciprofloxacin, trimethoprim-sulfamethoxazole, and ceftriaxone. Sensitivity shows susceptibility to piperacillin-tazobactam and meropenem. Creatinine is elevated (1.8 mg/dL, baseline 1.0).

Clinical Reasoning:

  1. Hospital-acquired = Higher resistance rates
  2. ESBL-producer suspected (resistant to 3rd-gen cephalosporin)
  3. Renal impairment = Adjust dosing, avoid nephrotoxic agents if possible

Antibiotic Choice: Piperacillin-tazobactam

  • βœ… Sensitive per culture
  • βœ… Beta-lactam/beta-lactamase inhibitor covers ESBL
  • βœ… Less nephrotoxic than aminoglycosides
  • βœ… Reserve carbapenems for truly resistant infections (stewardship)

Why not meropenem?

  • While effective, it's a carbapenem ("last resort" antibiotic)
  • Use increases carbapenem resistance risk
  • Save for infections resistant to all other options

Example 3: Drug Selection in Renal Failure

Clinical Scenario: A patient with end-stage renal disease on dialysis develops cellulitis. Culture grows MRSA.

Challenge: Many antibiotics require renal dose adjustment or are contraindicated.

AntibioticRenal ConsiderationsSuitable?
VancomycinRenally eliminated; requires monitoring but can dose around dialysisβœ… YES - Standard MRSA treatment
DaptomycinRenally eliminated; dose after dialysisβœ… YES - Alternative
LinezolidHepatically metabolized; no dose adjustment needed!βœ… YES - Easiest option
GentamicinRenally eliminated + nephrotoxic❌ Avoid if possible

Best choice: Linezolid (Zyvox)

  • No dose adjustment needed
  • Excellent tissue penetration for skin infections
  • Oral bioavailability = 100% (can switch from IV easily)

Example 4: Recognizing Adverse Drug Reactions

Clinical Scenario: A 65-year-old man on ciprofloxacin for prostatitis calls clinic on day 8 complaining of right ankle pain and swelling. He cannot bear weight. No injury recalled.

Recognition: 🚨 Fluoroquinolone-associated tendon rupture!

Immediate Actions:

  1. ⏹️ STOP ciprofloxacin immediately
  2. πŸ₯ Refer to orthopedics (urgent evaluation)
  3. πŸ’Š Switch antibiotic: Use alternative for prostatitis (trimethoprim-sulfamethoxazole, doxycycline)
  4. πŸ“ Document allergy: Note "tendon rupture" to prevent future fluoroquinolone prescriptions

Learning point: Black box warnings exist for a reason! Risk factors (age >60, corticosteroids) dramatically increase adverse event rates.


⚠️ Common Mistakes in Antibiotic Prescribing

Mistake #1: "Viral Infection? Here's a Z-pack!"

❌ The error: Prescribing antibiotics for viral upper respiratory infections, bronchitis, or flu

βœ… The fix:

  • Educate patients: Antibiotics don't work on viruses
  • Viral URIs resolve in 7-10 days without antibiotics
  • Symptomatic treatment: Fluids, rest, antipyretics
  • Consider delayed prescribing strategy

Consequence: Drives resistance, exposes patients to side effects with zero benefit

Mistake #2: Ignoring Drug Interactions

❌ The error: Prescribing clarithromycin to a patient on atorvastatin

βœ… The fix:

  • Check CYP3A4 interactions for macrolides
  • Use azithromycin instead (no CYP inhibition)
  • Or temporarily hold statin during short antibiotic course

Consequence: Statin levels skyrocket β†’ rhabdomyolysis (muscle breakdown) risk

Mistake #3: Inadequate Duration

❌ The error: "Stop antibiotics when you feel better"

βœ… The fix:

  • Prescribe full recommended course (evidence-based durations)
  • Educate: Feeling better β‰  infection eradicated
  • Premature stopping allows resistant bacteria to survive

Exception: Some infections now have shorter, equally effective courses (uncomplicated UTI: 3 days vs. 7 days)

Mistake #4: Forgetting Allergy Cross-Reactivity

❌ The error: Giving ceftriaxone to patient with documented anaphylaxis to penicillin

βœ… The fix:

  • Determine allergy type: Rash vs. anaphylaxis
  • True IgE-mediated penicillin allergy: ~10% cross-reactivity with cephalosporins
  • Anaphylaxis: Avoid all beta-lactams except aztreonam
  • Rash only: Later-generation cephalosporins often safe

Consider: Many "penicillin allergies" are not true allergies - penicillin allergy testing can expand treatment options

Mistake #5: One Size Fits All Dosing

❌ The error: Same dose for 50 kg elderly woman and 120 kg young man

βœ… The fix:

  • Adjust for weight (especially aminoglycosides, vancomycin)
  • Adjust for renal function (most antibiotics)
  • Adjust for hepatic function (macrolides, some others)
  • Consider age-related pharmacokinetic changes

🎯 Key Takeaways

πŸ“‹ Quick Reference Card: Antibiotic Essentials

ClassMechanismKey UseMajor Side Effect
Beta-lactamsCell wall synthesis βŠ—Broad use, first-line many infectionsHypersensitivity
Aminoglycosides30S ribosome (protein synthesis βŠ—)Gram- sepsis, synergyNephro/ototoxicity
FluoroquinolonesDNA gyrase βŠ—UTI, respiratory, bonesTendon rupture, CNS
Macrolides50S ribosome (protein synthesis βŠ—)Atypical pneumonia, penicillin alternativeGI, QT prolongation
Tetracyclines30S ribosome (protein synthesis βŠ—)Atypicals, Lyme, acneTeeth staining (kids)
VancomycinCell wall synthesis βŠ—MRSA, serious Gram+Red Man Syndrome

🧠 Memory Aid: "RESISTANCE MECHANISMS"

  • Ribosomal modification (target change)
  • Efflux pumps (kick drug out)
  • Synthesis of inactivating enzymes
  • Impermeability (porin loss)
  • Substitution of target (altered PBPs)
  • Transfer of resistance genes
  • Altered metabolic pathway (bypass)
  • New target synthesis (PBP2a in MRSA)
  • Careful use (prevention strategy)
  • Education of prescribers and patients

🎯 Clinical Decision Framework

  1. Is antibiotic needed? (Bacterial vs. viral)
  2. What's the likely organism? (Empiric therapy)
  3. What's the site of infection? (Penetration matters)
  4. What's the severity? (Oral vs. IV, narrow vs. broad)
  5. Any contraindications? (Allergies, pregnancy, age, organ function)
  6. Get cultures before starting (De-escalate later)
  7. Monitor response & adjust (Stewardship in action)

πŸ”¬ Final Thoughts

Antimicrobial pharmacology represents the intersection of chemistry, microbiology, and clinical medicine. Every prescription decision carries weight - not just for the individual patient, but for public health. As a future healthcare provider, you are a steward of these precious resources.

Remember:

  • 🎯 Narrow is better when possible
  • πŸ”¬ Cultures guide optimal therapy
  • ⏱️ Duration matters (not too short, not too long)
  • πŸ›‘οΈ Resistance is inevitable, but we control the speed
  • πŸ“š Guidelines exist - use them!
  • πŸ‘₯ Antimicrobial stewardship is everyone's responsibility

πŸ“š Further Study

  1. CDC Antibiotic Resistance Threats Report: https://www.cdc.gov/drugresistance/biggest-threats.html - Updated data on resistance rates and "urgent threats"

  2. Johns Hopkins Antibiotic Guide: https://www.hopkinsguides.com/hopkins/index/Johns_Hopkins_ABX_Guide - Comprehensive, regularly updated clinical decision support

  3. Sanford Guide to Antimicrobial Therapy: https://www.sanfordguide.com - Gold standard pocket reference (subscription required, but often free through institutions)


Next lesson preview: We'll explore gastrointestinal pharmacology, covering drugs for acid-related disorders, antiemetics, laxatives, and inflammatory bowel disease. See you there! πŸš€πŸ’Š